Protein ubiquitylation in pancreatic cancer

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 1462-1472

  Bonacci, Thomas ^a   Roignot, Julie ^a   Soubeyran, Philippe ^a  

^a INSERM   (France)

Author keywords

Cancer; Pancreas; Ubiquitin; Ubiquitylation

Indexed keywords

BORTEZOMIB; GEMCITABINE; HYDROLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; MYOSIN HEAVY CHAIN; PI 083; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN KINASE PIM 1; SALINOSPORAMIDE A; SMAD4 PROTEIN; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

BINDING SITE; BIOLOGICAL ACTIVITY; CACHEXIA; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CLINICAL TRIAL; COMPETITIVE INHIBITION; DNA REPAIR; DRUG TREATMENT FAILURE; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME SUBSTRATE; GENETIC TRANSCRIPTION; HUMAN; INCIDENCE; MALIGNANT TRANSFORMATION; METASTASIS; METASTATIC PANCREATIC CARCINOMA; MOLECULAR RECOGNITION; MONOTHERAPY; NONHUMAN; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS ISLET BETA CELL; PANCREAS TUMOR; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATED PROTEINS; UBIQUITINATION;

EID: 77957943643     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.133     Document Type: Review

References (85)

1. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., and Thun, M.J. (2006) Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130.
2. Real, F.X. (2003) A "catastrophic hypothesis" for pancreas cancer progression. Gastroenterology 124, 1958-1964.
3. Van Cutsem, E., Aerts, R., Haustermans, K., Topal, B., Van Steenbergen, W., and Verslype, C. (2004) Systemic treatment of pancreatic cancer. Eur. J. Gastroenterol. Hepatol. 16, 265-274.
4. Garcea, G., Neal, C.P., Pattenden, C.J., Steward, W.P., and Berry, D.P. (2005) Molecular prognostic markers in pancreatic cancer: a systematic review. Eur. J. Cancer 41, 2213-2236. (Pubitemid 41415597)
5. Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., Hong, S.M., Fu, B., Lin, M.T., Calhoun, E.S., Kamiyama, M., Walter, K., Nikolskaya, T., Nikolsky, Y., Hartigan, J., Smith, D.R., Hidalgo, M., Leach, S.D., Klein, A.P., Jaffee, E.M., Goggins, M., Maitra, A., Iacobuzio-Donahue, C., Eshleman, J.R., Kern, S.E., Hruban, R.H., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V.E., and Kinzler, K.W. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806.
6. Jaffee, E.M., Hruban, R.H., Canto, M., and Kern, S.E. (2002) Focus on pancreas cancer. Cancer Cell 2, 25-28.
7. Moore, P.S., Orlandini, S., Zamboni, G., Capelli, P., Rigaud, G., Falconi, M., Bassi, C., Lemoine, N.R., and Scarpa, A. (2001) Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br. J. Cancer 84, 253-262. (Pubitemid 32113454)
8. Rozenblum, E., Schutte, M., Goggins, M., Hahn, S.A., Panzer, S., Zahurak, M., Goodman, S.N., Sohn, T.A., Hruban, R.H., Yeo, C.J., and Kern, S.E. (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57, 1731-1734.
9. Yang, X.J. (2005) Multisite protein modification and intramolecular signaling. Oncogene 24, 1653-1662.
10. Blume-Jensen, P. and Hunter, T. (2001) Oncogenic kinase signalling. Nature 411, 355-365.
11. Sun, L. and Chen, Z.J. (2004) The novel functions of ubiquitination in signaling. Curr. Opin. Cell Biol. 16, 119-126.
12. Petroski, M.D. (2008) The ubiquitin system, disease, and drug discovery. BMC Biochem. 9(Suppl 1), S7.
13. Goldstein, G. (1974) Isolation of bovine thymin: a polypeptide hormone of the thymus. Nature 247, 11-14.
14. Ciechanover, A. (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 6, 79-87.
15. Pickart, C.M. and Eddins, M.J. (2004) Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta 1695, 55-72.
16. Ye, Y. and Rape, M. (2009) Building ubiquitin chains: E2 enzymes at work. Nat. Rev. Mol. Cell Biol. 10, 755-764.
17. Nijman, S.M., Luna-Vargas, M.P., Velds, A., Brummelkamp, T.R., Dirac, A.M., Sixma, T.K., and Bernards, R. (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773-786. (Pubitemid 41721026)
18. Herrmann, J., Lerman, L.O., and Lerman, A. (2007) Ubiquitin and ubiquitin-like proteins in protein regulation. Circ. Res. 100, 1276-1291.
19. Haas, A.L., Ahrens, P., Bright, P.M., and Ankel, H. (1987) Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J. Biol. Chem. 262, 11315-11323.
20. Podolsky, R., Prasad Linga-Reddy, M.V., and She, J.X. (2009) Analyses of multiple single-nucleotide polymorphisms in the SUMO4/IDDM5 region in affected sib-pair families with type I diabetes. Genes Immun. 10(Suppl 1), S16-20.
21. Dikic, I., Wakatsuki, S., and Walters, K.J. (2009) Ubiquitin-binding domains - from structures to functions. Nat. Rev. Mol. Cell Biol. 10, 659-671.
22. Upadhya, S.C. and Hegde, A.N. (2007) Role of the ubiquitin proteasome system in Alzheimer's disease. BMC Biochem. 8(Suppl 1), S12.
23. Cookson, M.R. (2005) The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29-52.
24. Finkbeiner, S. and Mitra, S. (2008) The ubiquitin-proteasome pathway in Huntington's disease. TheScientificWorldJOURNAL 8, 421-433.
25. Wing, S.S. (2008) The UPS in diabetes and obesity. BMC Biochem. 9(Suppl 1), S6.
26. Nury, D., Doucet, C., and Coux, O. (2007) Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting. BMC Biochem. 8(Suppl 1), S7. (Pubitemid 351814000)
27. Turnbull, E.L., Rosser, M.F., and Cyr, D.M. (2007) The role of the UPS in cystic fibrosis. BMC Biochem. 8(Suppl 1), S11.
28. Rotin, D. (2008) Role of the UPS in Liddle syndrome. BMC Biochem. 9(Suppl 1), S5.
29. Alkalay, I., Yaron, A., Hatzubai, A., Orian, A., Ciechanover, A., and Ben-Neriah, Y. (1995) Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 92, 10599-10603.
30. Xiao, G., Harhaj, E.W., and Sun, S.C. (2001) NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol. Cell 7, 401-409. (Pubitemid 32206507)
31. Deng, L., Wang, C., Spencer, E., Yang, L., Braun, A., You, J., Slaughter, C., Pickart, C., and Chen, Z.J. (2000) Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351-361.
32. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., and Yu, X.F. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060. (Pubitemid 37386201)
33. Margottin, F., Bour, S.P., Durand, H., Selig, L., Benichou, S., Richard, V., Thomas, D., Strebel, K., and Benarous, R. (1998) A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1, 565-574. (Pubitemid 128374692)
34. Willey, R.L., Maldarelli, F., Martin, M.A., and Strebel, K. (1992) Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J. Virol. 66, 7193-7200.
35. Coscoy, L. and Ganem, D. (2000) Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc. Natl. Acad. Sci. U. S. A. 97, 8051-8056.
36. Coscoy, L., Sanchez, D.J., and Ganem, D. (2001) A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J. Cell Biol. 155, 1265-1273. (Pubitemid 34286275)
37. Hoeller, D. and Dikic, I. (2009) Targeting the ubiquitin system in cancer therapy. Nature 458, 438-444.
38. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299. (Pubitemid 27220766)
39. Kubbutat, M.H., Jones, S.N., and Vousden, K.H. (1997) Regulation of p53 stability by Mdm2. Nature 387, 299-303.
40. Cardozo, T. and Pagano, M. (2007) Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes. BMC Biochem. 8(Suppl 1), S9. (Pubitemid 351813998)
41. Bloom, J. and Pagano, M. (2003) Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin. Cancer Biol. 13, 41-47.
42. Guardavaccaro, D. and Pagano, M. (2004) Oncogenic aberrations of cullin-dependent ubiquitin ligases. Oncogene 23, 2037-2049.
43. Wang, Q., Moyret-Lalle, C., Couzon, F., Surbiguet-Clippe, C., Saurin, J.C., Lorca, T., Navarro, C., and Puisieux, A. (2003) Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene 22, 1486-1490. (Pubitemid 36390597)
44. Bosaeus, I., Daneryd, P., Svanberg, E., and Lundholm, K. (2001) Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int. J. Cancer 93, 380-383.
45. Splinter, T.A. (1992) Cachexia and cancer: a clinician's view. Ann. Oncol. 3(Suppl 3), 25-27.
46. Houten, L. and Reilley, A.A. (1980) An investigation of the cause of death from cancer. J. Surg. Oncol. 13, 111-116.
47. Todorov, P., Cariuk, P., McDevitt, T., Coles, B., Fearon, K., and Tisdale, M. (1996) Characterization of a cancer cachectic factor. Nature 379, 739-742.
48. Cariuk, P., Lorite, M.J., Todorov, P.T., Field, W.N., Wigmore, S.J., and Tisdale, M.J. (1997) Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br. J. Cancer 76, 606-613.
49. Lorite, M.J., Smith, H.J., Arnold, J.A., Morris, A., Thompson, M.G., and Tisdale, M.J. (2001) Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br. J. Cancer 85, 297-302.
50. Bodine, S.C., Latres, E., Baumhueter, S., Lai, V.K., Nunez, L., Clarke, B.A., Poueymirou, W.T., Panaro, F.J., Na, E., Dharmarajan, K., Pan, Z.Q., Valenzuela, D.M., DeChiara, T.M., Stitt, T.N., Yancopoulos, G.D., and Glass, D.J. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704-1708.
51. Gomes, M.D., Lecker, S.H., Jagoe, R.T., Navon, A., and Goldberg, A.L. (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. U. S. A. 98, 14440-14445.
52. Clarke, B.A., Drujan, D., Willis, M.S., Murphy, L.O., Corpina, R.A., Burova, E., Rakhilin, S.V., Stitt, T.N., Patterson, C., Latres, E., and Glass, D.J. (2007) The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6, 376-385.
53. Kedar, V., McDonough, H., Arya, R., Li, H.H., Rockman, H.A., and Patterson, C. (2004) Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc. Natl. Acad. Sci. U. S. A.101, 18135-18140.
54. Kwak, K.S., Zhou, X., Solomon, V., Baracos, V.E., Davis, J., Bannon, A.W., Boyle, W.J., Lacey, D.L., and Han, H.Q. (2004) Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia. Cancer Res. 64, 8193-8198.
55. Hahn, S.A., Schutte, M., Hoque, A.T., Moskaluk, C.A., da Costa, L.T., Rozenblum, E., Weinstein, C.L., Fischer, A., Yeo, C.J., Hruban, R.H., and Kern, S.E. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-353.
56. Xu, J. and Attisano, L. (2000) Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 97, 4820-4825.
57. Maurice, D., Pierreux, C.E., Howell, M., Wilentz, R.E., Owen, M.J., and Hill, C.S. (2001) Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability. J. Biol. Chem. 276, 43175-43181.
58. Wan, M., Huang, J., Jhala, N.C., Tytler, E.M., Yang, L., Vickers, S.M., Tang, Y., Lu, C., Wang, N., and Cao, X. (2005) SCF(beta-TrCP1) controls Smad4 protein stability in pancreatic cancer cells. Am. J. Pathol. 166, 1379-1392.
59. Kallifatidis, G., Rausch, V., Baumann, B., Apel, A., Beckermann, B.M., Groth, A., Mattern, J., Li, Z., Kolb, A., Moldenhauer, G., Altevogt, P., Wirth, T., Werner, J., Schemmer, P., Buchler, M.W., Salnikov, A.V., and Herr, I. (2009) Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 58, 949-963.
60. Muerkoster, S., Arlt, A., Sipos, B., Witt, M., Grossmann, M., Kloppel, G., Kalthoff, H., Folsch, U.R., and Schafer, H. (2005) Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res. 65, 1316-1324.
61. Ni, X.G., Zhou, L., Wang, G.Q., Liu, S.M., Bai, X.F., Liu, F., Peppelenbosch, M.P., and Zhao, P. (2008) The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer. Mol. Med. 14, 582-589.
62. Verma, A., Guha, S., Wang, H., Fok, J.Y., Koul, D., Abbruzzese, J., and Mehta, K. (2008) Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin. Cancer Res. 14, 1997-2005.
63. Nakayama, K., Qi, J., and Ronai, Z. (2009) The ubiquitin ligase Siah2 and the hypoxia response. Mol. Cancer Res. 7, 443-451.
64. Koong, A.C., Mehta, V.K., Le, Q.T., Fisher, G.A., Terris, D.J., Brown, J.M., Bastidas, A.J., and Vierra, M. (2000) Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 48, 919-922.
65. Schmidt, R.L., Park, C.H., Ahmed, A.U., Gundelach, J.H., Reed, N.R., Cheng, S., Knudsen, B.E., and Tang, A.H. (2007) Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue. Cancer Res. 67, 11798-11810.
66. Zhai, H., Shi, Y., Jin, H., Li, Y., Lu, Y., Chen, X., Wang, J., Ding, L., Wang, X., and Fan, D. (2008) Expression of calcyclin-binding protein/Siah-1 interacting protein in normal and malignant human tissues: an immunohistochemical survey. J. Histochem. Cytochem. 56, 765-772.
67. Matsuzawa, S.I. and Reed, J.C. (2001) Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol. Cell 7, 915-926.
68. Chen, J., Kobayashi, M., Darmanin, S., Qiao, Y., Gully, C., Zhao, R., Kondo, S., Wang, H., Yeung, S.C., and Lee, M.H. (2009) Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation. Am. J. Pathol. 175, 400-411.
69. Zhang, Q., Meng, Y., Zhang, L., Chen, J., and Zhu, D. (2009) RNF13: a novel RING-type ubiquitin ligase overexpressed in pancreatic cancer. Cell Res. 19, 348-357.
70. Ling, Y.H., Liebes, L., Jiang, J.D., Holland, J.F., Elliott, P.J., Adams, J., Muggia, F.M., and Perez-Soler, R. (2003) Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res. 9, 1145-1154.
71. Ling, Y.H., Liebes, L., Ng, B., Buckley, M., Elliott, P.J., Adams, J., Jiang, J.D., Muggia, F.M., and Perez-Soler, R. (2002) PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol. Cancer Ther. 1, 841-849.
72. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S., and Elliott, P.J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622.
73. Adams, J. (2002) Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr. Opin. Chem. Biol. 6, 493-500.
74. Shah, S.A., Potter, M.W., McDade, T.P., Ricciardi, R., Perugini, R.A., Elliott, P.J., Adams, J., and Callery, M.P. (2001) 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem. 82, 110-122.
75. Bold, R.J., Virudachalam, S., and McConkey, D.J. (2001) Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 100, 11-17.
76. McDade, T.P., Perugini, R.A., Vittimberga, F.J., Jr., and Callery, M.P. (1999) Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells. Surgery 126, 371-377.
77. Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., Adams, J., and Anderson, K.C. (2002) NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 277, 16639-16647.
78. Alberts, S.R., Foster, N.R., Morton, R.F., Kugler, J., Schaefer, P., Wiesenfeld, M., Fitch, T.R., Steen, P., Kim, G.P., and Gill, S. (2005) PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann. Oncol. 16, 1654-1661.
79. Nawrocki, S.T., Carew, J.S., Pino, M.S., Highshaw, R.A., Andtbacka, R.H., Dunner, K., Jr., Pal, A., Bornmann, W.G., Chiao, P.J., Huang, P., Xiong, H., Abbruzzese, J.L., and McConkey, D.J. (2006) Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 66, 3773-3781.
80. Marten, A., Zeiss, N., Serba, S., Mehrle, S., von Lilienfeld-Toal, M., and Schmidt, J. (2008) Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma. Mol. Cancer Ther. 7, 3624-3631.
81. Ikeda, N., Adachi, M., Taki, T., Huang, C., Hashida, H., Takabayashi, A., Sho, M., Nakajima, Y., Kanehiro, H., Hisanaga, M., Nakano, H., and Miyake, M. (1999) Prognostic significance of angiogenesis in human pancreatic cancer. Br. J. Cancer 79, 1553-1563.
82. LeBlanc, R., Catley, L.P., Hideshima, T., Lentzsch, S., Mitsiades, C.S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C.S., Adams, J., Gupta, D., Richardson, P.G., Munshi, N.C., and Anderson, K.C. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62, 4996-5000.
83. Sloss, C.M., Wang, F., Liu, R., Xia, L., Houston, M., Ljungman, D., Palladino, M.A., and Cusack, J.C., Jr. (2008) Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin. Cancer Res. 14, 5116-5123.
84. McConkey, D.J. and Zhu, K. (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updat. 11, 164-179.
85. Kazi, A., Lawrence, H., Guida, W.C., McLaughlin, M.L., Springett, G.M., Berndt, N., Yip, R.M., and Sebti, S.M. (2009) Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle 8, 1940-1951.